

Research

Open Access

Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors

Robson Ferrigno*¹, Paulo Eduardo Ribeiro dos Santos Novaes¹, Maria Letícia Gobo Silva¹, Ines Nobuko Nishimoto², Wilson Toshihiko Nakagawa³, Benedito Mauro Rossi³, Fábio de Oliveira Ferreira³ and Ademar Lopes³

Address: ¹Department of Radiation Oncology, Hospital do Câncer A. C. Camargo, Rua Prof. Antonio Prudente, 211, São Paulo, SP 01509-900, Brazil, ²Department of Biostatistics, Fundação Antonio Prudente, Rua Prof. Antonio Prudente, 211, São Paulo, SP 01509-900, Brazil and ³Department of Pelvic Surgery, Hospital do Câncer A. C. Camargo, Rua Prof. Antonio Prudente, 211, São Paulo, SP 01509-900, Brazil

Email: Robson Ferrigno* - rferrigno@uol.com.br; Paulo Eduardo Ribeiro dos Santos Novaes - novaespe@uol.com.br; Maria Letícia Gobo Silva - Gobo@yahoo.com; Ines Nobuko Nishimoto - nishimoto@uol.com.br; Wilson Toshihiko Nakagawa - nakagawaw@uol.com.br; Benedito Mauro Rossi - bmrossi@aol.com; Fábio de Oliveira Ferreira - ferreiraf@uol.com.br; Ademar Lopes - alopes@uol.com.br

* Corresponding author

Published: 28 March 2006

Received: 15 November 2005

Radiation Oncology 2006, 1:5 doi:10.1186/1748-717X-1-5

Accepted: 28 March 2006

This article is available from: <http://www.ro-journal.com/content/1/1/5>

© 2006 Ferrigno et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose: To report the retrospective analysis of patients with locally advanced rectal cancer treated with neoadjuvant radiochemotherapy.

Methods and Materials: From January 1994 to December 2003, 101 patients with fixed (25%) or semi-fixed (75%) rectal adenocarcinoma were treated by preoperative radiotherapy with a dose of 45Gy at the whole pelvis and 50.4Gy at primary tumor, concomitant to four weekly chemotherapies with 5-Fluorouracil (425 mg/m²) and Leucovorin (20 mg/m²). In 71 patients (70.3%) the primary tumor was located up to 6 cm from the anal verge and in 30 (29.7%) from 6.5 cm to 10 cm. Age, gender, tumor fixation, tumor distance from the anal verge, clinical response, surgical technique, and postoperative TNM stage were the prognostic factors analyzed for overall survival (OS), disease-free survival (DFS), and local control (LC) at five years.

Results: Median follow-up time was 38 months (range, 2–141). Complete response was observed in eight patients (7.9%), partial in 54 (53.4%) and absence in 39 (38.7%). OS, DFS and LC were 52.6%, 53.8%, and 75.9%, respectively. Distant metastasis occurred in 40 (39.6%) patients, local recurrence in 20 (19.8%) and both in 16 (15.8%). Patients with fixed tumors had lower OS (17% Vs 65.6%; $p < 0.001$), DFS (31.2% Vs 60.9%; $p = 0.005$), and LC (58% Vs 82%; $p = 0.004$). Patients with tumors more than 6 cm above the anal verge had better LC (93% Vs 69%; $p = 0.04$). The postoperative TNM stage was a significant factor for DFS (I:64.1%, II:69.6%, III:35.2%, IV:11.1%; $p < 0.001$) and for LC (I:75.7%, II: 92.9%, III:54.1%, IV:100%; $p = 0.005$). Patients with positive lymph nodes had worse OS (37.9% Vs 70.4%, $p = 0.006$), DFS (32% Vs 72.7%, $p < 0.001$) and LC (56.2% Vs 93.4%; $p < 0.001$).

Conclusion: This study suggests that the neoadjuvant treatment employed was effective for local control. Fixation of the lesion and lymph nodes metastasis were the main adverse prognostic factors. Distant failures were frequent, supporting the need of new drugs for adjuvant chemotherapy.

Table 1: Patients and tumor characteristics.

Patient number	101
Period	Jan/1994 – Dec/2003
Age (year)	
Median	62
Range	(25 – 84)
Gender	
Male	52 (51.5%)
Female	49 (48.5%)
Tumor distance from the anal verge	
0–6 cm	71 (70.3%)
6.5–10 cm	30 (29.7%)
Tumor mobility	
Fixed	25 (24.7%)
Semi-fixed	76 (75.3%)

Introduction

The employment of preoperative radiotherapy (RT) combined or not with chemotherapy (CT) has been used in the treatment of rectal cancer for the past two decades and its employ gradually increased as adjuvant therapy, especially in T3/T4 and/or N1/N2 tumors [1,2]. The strategy of performing preoperative instead of postoperative treatment, has the proven advantages of lower acute toxicity [3-6], lower total dose of radiation needed [4] and eventual tumor regression and downstaging to enable curative resection and even sphincter preservation [7-17]. Furthermore, some authors showed better local control with preoperative RT when compared to surgery alone [7-10,18,19]. Upon comparison with the postoperative radiochemotherapy approach for adjuvant treatment, data suggest that local control was better using preoperative radiochemotherapy [20]. In preoperative therapy, the association of CT increases pathologic downstaging when compared to radiation alone [21]. Theoretical advantages of the preoperative strategy include increased radiosensitivity due to more oxygenated cells and decrease of tumor seeding during surgery [22]. For patients with fixed or tethered tumors to adjacent structures, the goal of preoperative RT, preferably combined with CT, is to achieve maximal tumor regression to facilitate resection.

This study reports results on patients with fixed and semi-fixed adenocarcinoma of the rectum treated with preoperative radiochemotherapy, as well as the analysis of some prognostic factors that could have influenced the outcome.

Methods and materials

Patient and tumor characteristics

From January 1994 to December 2003, 101 patients with locally advanced rectal cancer, characterized by fixed or semi-fixed tumor, were treated with preoperative RT concomitant to CT. All patients had biopsy proven adenocar-

cinoma of the rectum and they were staged through physical exam, including digital rectal examination of the primary lesion by the same team of surgeons, chest radiograph, computerized tomography of the abdomen and pelvis, blood chemistries, HIV test and colonoscopy. Endorectal ultrasound was not used for staging these patients. A semi-fixed tumor was that with preserved mobility in at least one direction at digital rectal examination. The tumor distance from the anal verge was measured by colonoscopy. Table 1 summarizes the patients and tumor characteristics.

Radiotherapy

All patients received whole pelvic radiation with dose of 45Gy in 25 daily fractions of 1.8Gy, over five weeks, by four fields, followed by a boost to the primary tumor of up to 50.4Gy, with at least 2 cm margins, by three fields (one posterior and two laterals). The upper limit of all the pelvic fields was at the L5-S1 level and the lower one was 4 to 5 cm below the tumor. The lateral fields covered the sacrum and coccyx posteriorly and the femoral head anteriorly. The photon energy used was given by a 4 or 6 MV linear accelerator. The dose was prescribed to the 95% isodose line. All fields were treated daily and weighting was 2:1 for the posterior – anterior and laterals incidences, respectively, for four fields whole pelvis, and 2:1:1 for the posterior, right lateral, and left lateral portals, respectively, for three fields boost. Wedges of different degrees were employed over the lateral fields to homogenize the isodose distribution. The isodoses distribution was designed by 2D treatment planning system.

Chemotherapy

The CT was performed with two hours bolus infusion of 5-Fluorouracil (5-FU) and leucovorin (LV), once a week, with a median of four cycles (range: 2-6). The median dose of 5-FU per cycle was of 425 mg/m² (range: 88 – 800 mg/m²) and all patients treated with CT received 20 mg/m² of LV. During the radiochemotherapy course, acute toxicity was evaluated. If nausea, vomiting, diarrhea, mucositis or leucopenia were not controlled with medication, the treatment was temporarily interrupted. The decision of performing this weekly CT schedule instead of during the first and last week of RT course had the objective of maximize the radiation effect.

Adjuvant CT was employed in all patients with postoperative lymph-nodes metastasis and in those who presented unresectable primary tumor or intrabdominal disease dissemination during surgery. This CT was based on 5-FU and LV.

Preoperative evaluation and surgery

Four weeks after the radiochemotherapy course, all patients were evaluated and restaged by means of physical

examination, computerized tomography of the abdomen and pelvis, chest x-ray, blood chemistries, and colonoscopy. If at colonoscopy no tumor was visualized, patients were considered as having a complete clinical response, partial response was considered if tumor regressed more than 50% of the initial volume, and no response if the tumor did not regress more than 50%. Surgery was planned to take place four to six weeks after the radiochemotherapy course. The surgical technique was decided by the surgeon's team, based on tumor location, clinical response, and intraoperative findings. All patients treated with surgery underwent total mesorectal excision by means of anterior resection, abdominoperineal resection or pelvic exenteration. Postoperative stage was classified by the American Joint Committee on Cancer (AJCC) TNM staging system [23], based on pathologic findings. Patients with complete pathologic response were considered as stage 0 (T0N0M0).

Follow-up

Follow-up was performed at every 3 months in the first two years following completion of surgery, and at a minimum of 6 months thereafter. At each follow-up all patients underwent clinical examination and also a rectosigmoidoscopy in those treated with sphincter saving surgery. Chest radiograph and abdominopelvic computerized tomography were done every 6 months in the first 3 years and every 12 months thereafter or when clinically required.

Statistical analysis

All statistical analyses were performed with a software program Statistics/Data analysis (STATA Corporation, Houston: University of Texas; 2000). Overall survival (OS), disease free survival (DFS), and local control (LC) were calculated according to the actuarial method of Kaplan and Meier [24]. The calculation of OS, DFS and LC was performed from the date of diagnosis to the date of the event. Survival was measured from the date of diagnosis to death or last follow-up. Patients who died of diseases unrelated to cancer were censored. The prognostic factors analyzed were: patient's age, gender, pretreatment tumor status (fixation), tumor distance from the anal verge, clinical response to the neoadjuvant treatment by colonoscopy, surgical technique employed, and postoperative TNM stage. The log-rank test was used to compare the actuarial probabilities curves for OS, DFS and LC. Relative risk of death was determined by Cox regression analysis [25]. Comparison of categorical variables was performed using the chi-square (χ^2) test. Values of p lesser than 0.05 or 95% were considered as having a statistical significance. Last revision of this analysis was carried out in July 2005.

Results

Neoadjuvant treatment

Of the 101 patients treated, 7 (6.9%) did not complete the prescribed dose of preoperative RT because of persistent neutropenia and/or diarrhea. Of these, two died due to septicemia and the other five underwent surgery before the end of radiochemotherapy. Doses administered to these patients ranged from 14.4Gy to 39.6Gy at the whole pelvis. During the RT course, 88 (87.1%) patients received concomitant weekly CT. Thirteen patients (12.9%) did not receive CT because of inadequate clinical conditions. Temporary interruption of both treatment (RT and CT) with a median duration of one week, due to leucopenia, diarrhea or mucositis not controlled with medication, was necessary in 22 (21.8%) patients (grade 3 toxicity). The rate of treatment response, evaluated four weeks after the end of RT, was considered complete in eight (7.9%) patients, partial in 54 (53.4%), and null in 39 (38.6%). None of the patients developed tumor progression during or up to four weeks after RT.

Surgery

Surgery was performed four to six weeks after RT in 89 patients (88%). Of these, 83 (82%) had the primary tumor removed and 6 (5.9%) underwent only colostomy because of unresectable tumor and/or disease dissemination detected during laparotomy. All patients treated by surgery underwent total mesorectal excision and according to the surgical technique employed for tumor removal, 38 (37.6%) were by anterior resection (AR), 36 (35.6%) were by abdominoperineal resection (APR), and 9 (9%) were by pelvic exenteration. All 83 patients with surgical removal of the tumor had negative resection margins, including the circumferential one.

Twelve (11.8%) patients were not submitted to surgery because two died during the neoadjuvant treatment, five presented distant metastasis at restaging procedures and five refused surgery because they achieved complete clinical response after radiochemotherapy course. These last patients have been followed up every three months. One developed distant metastasis after 14 months of follow-up and died 17 months after diagnosis with no local failure. This patient was initially staged as T4 because of vaginal invasion. The other four patients are alive with no evidence of disease with median follow-up of 72 months (range: 48 – 96). These patients had the primary tumor located from 2 to 6 cm from the anal verge and they were considered candidates to APR by the surgeon prior to neoadjuvant treatment.

Sphincter preservation

Among 71 patients with distal rectal cancer (tumor up to 6 cm from the anal verge) and initially considered candidates to APR, 14 (19.7%) underwent sphincter-sparing

low AR and coloanal anastomosis. Of these, one patient had tumor located 2 cm from the anal verge, one had it located 3 cm away and the remaining at a 4 to 5 cm distance. In this group, the 5-year local control probability was of 58.8%. The patient with the tumor 2 cm from the anal verge was postoperative stage T3N2M0 and developed both local and distant failures. Adding these patients with the five with distal rectal cancer who refused surgery and did not develop local failure, the sphincter preservation rate among patients with initial indication of APR was of 26.8% (19/71).

Postoperative staging and surgical findings

The postoperative TNM staging of the 83 patients with primary tumor removed by surgery, according to AJCC is shown in Table 2. The primary tumor was not removed in six patients because it was unresectable in three, two had intrabdominal disease dissemination and one presented both. Among patients with the primary tumor removed by surgery, 33 (39.7%) had lymph-node metastasis at pathology report (N1/N2) and their T stage distribution was: T0:2 (2.4%); T1:2 (2.4%); T2:26 (31.3%); T3:42 (41.6%); and T4:11 (13.2%). Of the 25 patients with initially fixed tumors, 16 (64%) underwent tumor resection by AR (5 patients), APR (6 patients) or pelvic exenteration (5 patients).

Patient's follow-up and patterns of failure

Median follow-up time was 38 months (range, 2 - 141). At the time of this analysis, 46 patients (45.5%) were alive with no evidence of disease, 5 (4.9%) were alive with evidence of disease, 42 (41.6%) died due to the rectal cancer, 4 (4%) died of second primary tumor, and 4 (4%) died due of diseases unrelated to cancer. According to the pattern of failure, 24 (23.8%) patients developed only distant metastasis, 4 (4%) had only local recurrence, and 16 (15.8%) developed both. Two patients who developed only local failure were rescued by a second surgery. Eight (7.9%) patients developed second primary tumor. Of these, two had lung cancer and died; one had low grade non Hodgkin's lymphoma and is alive with no evidence of disease; one had bladder cancer and died of causes unrelated to cancer; one had kidney cancer and died of rectal cancer; one developed prostate cancer and is alive with no evidence of disease; one developed acute lymphoblastic leukemia and died of it, and one died due to a glioblastoma multiform of the brain.

Actuarial results and prognostic factors

Using the Kaplan-Meier actuarial method, probabilities of OS, DFS, and LC at five years for all patients were 52.6% (Figure 1), 53.8%, and 75.9%, respectively. For OS, age, gender, tumor location, postoperative TNM stage, and clinical response were not statistically significant factors. Patients with fixed tumor had worse 5-year OS (17% Vs

Table 2: Postoperative TNM staging distribution by AJCC

Stage	n (%)
0	2 (2.4%)
T0N0M0	2 (2.4%)
I	20 (24.1%)
T1N0M0	2 (2.4%)
T2N0M0	18 (21.7%)
II	26 (31.3%)
T3N0M0	22 (26.5%)
T4N0M0	4 (4.8%)
III	30 (36.1%)
T2N1-2M0	7 (8.4%)
T3N1-2M0	16 (19.3%)
T4N1-2M0	7 (8.4%)
IV	5 (6%)
T2N1M1	1 (1.2%)
T3N0M1	2 (2.4%)
T3N1M1	2 (2.4%)

Abbreviation: AJCC = American Joint Committee on Cancer.

65.7%; $p < 0.001$) (Figure 2) as well as those with positive postoperative lymph nodes (37.9% Vs 70.4%; $p = 0.006$) (Figure 3).

For DFS, age, gender, tumor location, surgical technique, and clinical response were not statistically significant factors. Patients with fixed tumors had worse DFS, as well as those with positive postoperative lymph-nodes (Table 3), and those with postoperative stages III and IV (Table 3 and figure 4).

The probability of LC at five years was not influenced by age, gender, clinical response, surgical technique, and postoperative T stage. Better 5-year LC was observed in patients with semi-fixed tumor (Table 3) and in those with tumor located above 6 cm from the anal verge (Table 3 and figure 5). Patients with postoperative stage III disease had lower 5-year local control, as well those with postoperative positive lymph-nodes (Table 3).

Estimated relative risk of death, calculated by Cox regression analysis, was higher among patients with fixed tumors and with postoperative positive lymph-nodes (Table 4).

Discussion

For locally advanced rectal cancer, the employment of pre-operative radiotherapy, preferably combined with chemotherapy, is an interesting treatment strategy due to the possibility of tumor downstaging, which leads to an enhanced resectability rate [11,12,14-17]. Other advantages of this treatment strategy, already reported in literature, include sterilization of the tumor bed, easier displacement of the small bowel and a lower total dose of radiation needed [5,26-29].




Figure 1
Actuarial overall survival probability for all patients.




Figure 2
Actuarial overall survival probability by tumor fixation.

In this study, all patients had locally advanced primary tumors and were classified as fixed or semi-fixed ones. After the radiochemotherapy course, 83 (82%) patients had the tumor resected with negative margins. The down-staging achieved was not precisely determined because the endorectal ultrasound was not used for staging, but 30 (29.7%) patients presented postoperative T0 – T2 tumors (Table 2). Furthermore, among 25 patients with fixed tumor and initially supposed to be unresectable, 16 (64%) was resected with negative margins. The actuarial 5-year local control rate of 75.9% was reasonable, considering the initial extension of the primary tumor. This result is consistent with other series from literature that report similar local control rates in patients with locally advanced tumors treated with preoperative radiotherapy with or without chemotherapy [12,15,16,30-37]. In our series, distant metastasis was the predominant pattern of

failure. This implies the need of new drugs for adjuvant treatment for these patients.

For resectable rectal tumors, preoperative RT seems to achieve better local control than the postoperative RT, as reported by the prospective and randomized German trial CAO/ARO/AIO 94 [20] and by two meta-analyses [38,39]. At our Institution, we still do not use preoperative RT for resectable tumors. This group of patients is at first treated with surgical resection and the indication of adjuvant treatment is determined by the pathology report. In the future, we will probably design a prospective and randomized phase III trial similar to the German one to compare preoperative with postoperative radiochemotherapy in the management of rectal cancer, even for resectable tumors.

Endorectal sonography can be useful for staging primary rectal tumors before surgery or preoperative radiochemotherapy, mainly for resectable tumors, which will help to elect the surgical technique. Although the accuracy of this

Table 3: Disease-free survival (DFS) and local control (LC) probability at five years by prognostic factors.

Prognostic factor	Category	DFS	P	LC	p
Tumor fixation	Semi-fixed	60.1%	0.005	81.9%	0.004
	Fixed	31.2%		58.2%	
Tumor distance from the anal verge	≤ 6 cm	48.1%	0.19	69.3%	0.043
	> 6 cm	67.1%		92.6%	
Postoperative stage	I	64.1%	<0.001	75.7%	0.005
	II	69.6%		92.9%	
	III	35.2%		54.1%	
	IV	11.1%		100%	
Postoperative N stage	N0	72.7%	<0.001	93.4%	<0.001
	N1/N2	32.0%		56.3%	

Table 4: Death risk according to the main prognostic factors by Cox multivariate regression analysis.

Variable	Category	HR*	[95% Conf. Interv.]	HR§	[95% Conf. Interv.]
Tumor fixation	Semi-fixed	1.0	Reference	1.0	Reference
	Fixed	3.87	(2.1 – 7.0)	2.64	(1.2 – 5.7)
Postoperative N stage	N0	1.0	Reference	1.0	Reference
	N1/N2	2.51	(1.3 – 4.9)	2.13	(1.0 – 4.4)

* Crude hazard risk

§ Adjusted hazard risk for age (median of 61 years)

exam is of approximately 70% [40,41], two recent studies with preoperative radiotherapy showed that it is insufficient to stage lymph-node involvement [42,43]. As all patients in our study at digital rectal examination had fixed or semi-fixed tumors, we did not use this exam during the staging procedures. Furthermore, postoperative pathology staging has been demonstrated to be a more accurate prognostic factor than the ultrasound staging [42-44].

Our Institution had already begun a prospective trial to test the possibility of avoiding surgery in patients with distal rectal adenocarcinoma who had presented pathologic complete response after 4 weeks of 50.4Gy of radiation at the whole pelvis, concomitant to CT with 5-FU (425 mg/m²/day) and LV (20 mg/m²/day) during the first 3 days and the last 3 days of RT [45]. These patients had received a radiotherapy boost at the primary tumor site with a 20Gy dose to replace surgical resection. Of 52 patients enrolled in this study, 10 (19.2%) achieved pathologic complete response and underwent radiation boost with no surgery. Of these, eight (80%) developed local recurrence within 3.7 to 8.8 months [46]. These findings have influenced our surgical team not to try sphincter preservation in distal rectal cancer, even after complete response to the radiochemotherapy course. Although sphincter preservation was not the main goal of our study, 19.7% patients initially candidate to APR underwent sphincter-sparing low AR and coloanal anastomosis. The 5-year local control in this group of patients was of 58.8%, suggesting that this strategy can compromise the local control.

In the management of distal rectal cancer, sphincter-sparing surgery is nowadays the main subject of controversy. One of the most important controversies is whether the degree of downstaging warrants this type of surgery [1]. Results of the German (CAO/ARO/AIO 94) randomized trial of preoperative versus postoperative combined radiochemotherapy suggest that this assessment is accurate [20]. A preliminary report of the NSABP R-03 trial revealed that the proportion of patients who underwent sphincter-sparing surgery and were disease free was higher in the preoperative than the postoperative arm (44% Vs 34%) and that the rate of sphincter preservation among

distal rectal cancer patients was 23% [47], similar to our results. Unfortunately, this trial was closed early because of small patient accrual. Other series from literature report the rate of sphincter preservation among patients with initially resectable distal rectal cancer ranging from 30% to 70%, with local failure of approximately 10% [15,16,47-56]. At our Institution, we believe that more prospective trials with longer follow-up are required to authorize a change of philosophy about margin resection.

Curiously, five patients in our study refused surgical resection after complete clinical response. Of these, four are still alive with no evidence of disease with a relative long follow-up (48 – 96 months). Probably, in this group of patients, tumors had some molecular markers which afforded them better response to preoperative therapy. Some authors have already studied selected molecular markers such as c-K-ras, thymidylate synthase, p53, p27Kkip1, DCC, EGFR, TP53, Ki-67, and apoptosis to identify this group of patients [57-64]. However, these studies are still limited and in the future, it will be imperative to identify some groups of patients by means of tissue collections to better choose the most appropriate therapy, including treatment with no surgery. Currently, observation is still not recommended for clinical complete responders. This affirmation is supported by the retrospective analysis of 488 patients with rectal cancer from the Memorial Sloan-Kettering Cancer Center treated with preoperative radiochemtoherapy. The clinical complete response rate was 19% and of these, pathologic complete response was observed in only 25%, showing that a significant percentage of clinical complete responders had persistent deep tumors or nodal involvement. The authors concluded that all patients with rectal cancer should undergo resection, regardless of their response to preoperative therapy [65]. Furthermore, locoregional tumor control should not be jeopardized by the justification of quality of life (QOL). Two recent analyses about QOL among patients with rectal cancer treated by preoperative radiotherapy showed that the presence of a permanent stoma did not affect the QOL outcome, when compared with patients treated with sphincter-sparing surgery [66,67].




Figure 3
Actuarial overall survival probability by postoperative lymph-nodes stage.




Figure 4
Actuarial disease-free survival probability by postoperative TNM stage.

In our study, the main adverse prognostic factors were fixation of the primary tumor and the presence of lymph-node metastasis (Table 3 and figure 2). Postoperative TNM stage was a prognostic indicator for disease-free survival and local control but not for overall survival (Table 3). These findings reflect the influence of tumor extension at the time of diagnosis, which can lead to distant dissemination, the main cause of death among our patients. Other series from literature also describe the postoperative TNM staging as a strong prognostic factor, especially if pelvic lymph-nodes are involved [42,44,68,69]. Clinical response did not influence the results. This lack of influence was probably due to the small number of patients who achieved clinical complete response. In the literature, some series show no correlation between tumor response to preoperative treatment and outcome [69-71], but most series suggest that there is improved outcome with increasing response to preoperative therapy [65,68,72-77]. In our series, better actuarial 5-year local control was observed among patients with primary tumor more than 6 cm from the anal verge (Table 3). The results of the Dutch CKVO 95-04 trial, which compared RT followed by surgery with only surgery, also showed better local control among patients with primary tumors located more than 5 cm from the anal verge [9]. The reason for better local control in patients with higher located tumors is probably related to the anatomic characteristics which facilitate tumor resection with wider margins. Surgical technique for tumor resection did not influence our results. Presumably, absence of a difference, including local control, is due to the fact that all patients treated with surgical resection had negative margins. Type of resection also did not influence local recurrence among the 1748 patients of the Dutch trial [9].

In our study, the acute toxicity observed was noticeable, however similar to that reported in literature. In general, the incidence of grade 3 acute toxicity during combined modality treatment ranges about 15–25% [1]. Care must be taken when CT is associated to RT during the preoperative therapy, mainly because of leucopenia that can lead patients to severe infections, septicemia and death. Whether preoperative radiochemotherapy is more toxic than only preoperative radiotherapy is an issue being addressed in the ongoing randomized EORTC trial 22921. Its preliminary results showed a greater incidence of grade 2 diarrhea in the CT group (34.3% Vs 17.3%; $p < 0.005$) and two patients died preoperatively from toxicity in the CT group [78]. To lessen the incidence of acute toxicity when combined radiochemotherapy is needed for pelvic




Figure 5
Actuarial local control probability by tumor distance from the anal verge.

tumors, intensity modulated radiation therapy (IMRT) treatment planning has been tested, because it can reduce the volume of irradiated small bowel and bone marrow [79,80]. In the future, preoperative trials with new drugs and radiotherapy with IMRT techniques will probably reduce the incidence of acute toxicity, thereby increasing the therapeutic ratio.

Conclusion

This retrospective analysis suggests that for locally advanced rectal cancer, the preoperative combined radio-chemotherapy strategy used was effective for local control. Sphincter preservation for distal rectal tumors can compromise the local control. The main adverse prognostic factors for survival and local control were fixation of the primary tumor and presence of pelvic lymph-nodes metastasis. Distant metastasis was the main pattern of failure, supporting the need of new drugs for adjuvant treatment, mainly among patients with positive lymph-nodes.

References

- Minsky BD: **Cancer of the Colon, Rectum and Anus.** *Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Salt Lake City; Educational Session 202* 2003.
- Kachnic LA, Moughan J, Thomas C, Owen J, Minsky BD: **The National Practice for patients receiving radiation therapy (RT) for carcinoma of the tectum (RC): Comparative analysis of treatment from the 1992-1994 and 1988-1989 Patterns of Care Studies by academic (AC) vs non-academic (NAC) centers.** *Int J Radiat Oncol Biol Phys* 2004, **57(2S)**:S182.
- Minsky BD, Cohen AM, Enker WE: **Combined modality therapy of rectal cancer: Decreased acute toxicity with the pre-operative approach.** *J Clin Oncol* 1992, **10**:1218-1224.
- Frykholm GJ, Isacson U, Nygard K, Montelius A, Jung B, Pahlman L, Glimelius B: **Preoperative radiotherapy in rectal carcinoma. Aspects of acute adverse effects and radiation technique.** *Int J Radiat Oncol Biol Phys* 1996, **35**:1039-1048.
- Holm T, Singnomklao T, Rutqvist LE, Cedermark B: **Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow up of two randomized trials.** *Cancer* 1996, **78**:968-976.
- Letschert JGJ, Lebesque JV, Aleman BMP, Bosset JF, Horiot JC, Cionini L, van Glabbeke M: **The volume effect in radiation-related late small bowel complications: Results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma.** *Radiother Oncol* 1994, **32**:116-123.
- Swedish Rectal Cancer Trial: **Improved survival with preoperative radiotherapy in resectable rectal cancer.** *N Engl J Med* 1997, **336**:980-987.
- Martling A, Holm T, Johansson H: **The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: Long-term follow-up of a population-based study.** *Cancer* 2001, **92**:896-902.
- Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJT, Pahlman L, Glimelius B, Leer JWH, van de Velde CJH: **Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.** *N Engl J Med* 2001, **345**:638-646.
- Medical Research Council Rectal Cancer Working Party: **Randomized trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer.** *Lancet* 1996, **348**:1605-1610.
- Chen ET, Mohiuddin M, Brodovsky H: **Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation.** *Int J Radiat Oncol Biol Phys* 1994, **30**:169-175.
- Minsky BD, Cohen AM, Enker WE, Kelsen D, Kemeny N, Ilson D, Guillem J, Saltz L, Frankel RN, Conti J: **Preoperative 5-FU, low dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.** *Int J Radiat Oncol Biol Phys* 1997, **37**:289-295.
- Wagman R, Minsky BD, Cohen AM, Enker W, Kelsen J, Frankel J, Conti J: **Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: Long term follow-up.** *Int J Radiat Oncol Biol Phys* 1998, **42**:51-57.
- Chan AKP, Wong AO, Langevin JM: **Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: A phase II dose escalation study.** *Int J Radiat Oncol Biol Phys* 2000, **48**:843-856.
- Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lurch PM, Guber G, Wolff R, Rich TA, Skibber J: **Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience.** *Int J Radiat Oncol Biol Phys* 1999, **44**:1027-1038.
- Janjan NA, Crane CN, Feig BW, Clary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J: **Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.** *Int J Radiat Oncol Biol Phys* 2000, **47**:713-718.
- Mohiuddin M, Regine WF, John WJ: **Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response.** *Int J Radiat Oncol Biol Phys* 2000, **46**:883-888.
- Cedermark B, Johansson H, Rutqvist LE: **The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma: A prospective randomized trial.** *Cancer* 1995, **75**:2269-2275.
- Dahlberg M, Glimelius B, Pahlman L, Leer JWH, van de Velde CJH: **Improved survival and reduction in local failure rates after preoperative radiotherapy: Evidence for the generalizability of the results of Swedish Rectal Cancer Trial.** *Ann Surg* 1999, **229**:493-497.
- Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R: **Preoperative versus postoperative chemoradiotherapy for rectal cancer.** *N Engl J Med* 2004, **351**:1731-1740.
- Minsky BD: **Multidisciplinary management of resectable rectal cancer.** *Oncology* 1996, **10**:1701-1714.
- Skibber JM, Hoff PM, Minsky BD: **Cancer of the rectum.** In *Cancer: Principles and Practice of Oncology* Sixth edition. Edited by: Devita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Williams & Wilkins; 2001:1271-1318.
- Colon and rectum: *American Joint Committee on Cancer. AJCC cancer staging manual* 6th edition. New York: Springer; 2002:112-119.
- Kaplan EL, Meier P: **Non parametric estimation from incomplete observation.** *J Am Stat Assoc* 1958, **53**:457-481.
- Cox DR: **Regression models and life table (with discussion).** *J R Stat Soc* 1972, **13**:187-220.
- Acker JC, Marks LB: **The lack of impact of pelvic irradiation on small bowel mobility: implications for radiotherapy treatment planning.** *Int J Radiat Oncol Biol Phys* 1995, **32**:1473-1475.
- Minsky BD, Conti JA, Huang Y, Knopf K: **Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.** *J Clin Oncol* 1995, **13**:1409-1416.
- Ota DM: **Preoperative radiotherapy for rectal cancer: benefits and controversies.** *Ann Surg Oncol* 1996, **3**:419-420.
- Glimelius B, Isacson U, Jung B, Pahlman L: **Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment.** *Int J Radiat Oncol Biol Phys* 1997, **37**:281-287.
- Berman SM: **Organ and functional preservation in the management of anorectal cancers.** *Cancer Invest* 1995, **13**:96-107.
- Mendenhall WM, Bland KI, Souba WW, Sombeck MD, Copeland EM, Million RR: **Preoperative irradiation for clinically resectable rectal adenocarcinoma.** *Semin Radiat Oncol* 1993, **3**:48-54.
- Minsky BD, Cohen AM: **Conservative management of invasive rectal cancer: Alternative to abdomino-perineal resection.** *Oncology* 1989, **3**:137-148.
- Freedman GM, Coia LR: **Adjuvant and neoadjuvant treatment of rectal cancer.** *Semin Oncol* 1995, **22**:611-624.

34. Moutardier V, Tardat E, Giovannini M, Ielong B, Guiramand J, Magnin V, Houvenaeghel G, Deopero JR: **Long-term results of preoperative radiotherapy for 113 cases of uT3 and uT4 rectal cancer: a need for long-term follow-up.** *Dis Colon Rectum* 2003, **46**:1194-1199.
35. Mendenhall WM, Vauthey JN, Zlotecki RA, Marsh RD, Copeland EM 3rd: **Preoperative chemoradiation for locally advanced rectal adenocarcinoma – the University of Florida experience.** *Semin Surg Oncol* 2003, **21**:261-264.
36. Sanfilippo NJ, Crane CH, Skibber J, Feig B, Abbruzzese L, Curley S, Hoff P, Wolff RA, Janjan NA: **T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.** *Int J Radiat Oncol Biol Phys* 2001, **51**:176-183.
37. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Saltz L, Frankel J: **The efficacy of preoperative 5-Fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.** *Cancer* 1993, **71**:3486-3492.
38. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M: **Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.** *JAMA* 2000, **284**:1008-1015.
39. Gray R, Hills R, Birmingham RS, Clarke M, Oxford RP, Brussels MB, Piedbois P: **Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials.** *The Lancet* 2001, **358**:1291-1304.
40. Lindmark GE, Kraaz WG, Elvin PAB: **Rectal cancer: evaluation of staging with endosonography.** *Radiology* 1997, **204**:533-538.
41. Kruskal JB, Kane RA, Sentovich SM: **Pitfalls and sources of error in staging rectal cancer with endorectal US.** *Radiographics* 1997, **17**:609-626.
42. Chapet O, Romestaing P, Mornex F, Souquet JC, Favrel V, Ardiet JM, Hombres A, Gerard JP: **Preoperative radiotherapy for rectal adenocarcinoma: which are strong prognostic factors?** *Int J Radiat Oncol Biol Phys* 2005, **61**:1371-1377.
43. Roman S, Cenni JC, Roy P, Pujol V, Napoleon B, Keriven-Souquet O, Souquet JC: **Value of rectal ultrasound in predicting staging and outcome in patients with rectal adenocarcinoma.** *Dis Colon Rectum* 2004, **47**:1323-1330.
44. Chan AKP, Wong A, Jenken D, Heine J, Buie D, Johnson D: **Post-treatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.** *Int J Radiat Oncol Biol Phys* 2005, **61**:665-677.
45. Rossi BM, Nakagawa WT, Novaes PE, David Filho WJ, Lopes A: **Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: A prospective trial.** *Annals of Surgical Oncology* 1998, **5**:113-118.
46. Nakagawa WT, Rossi BM, Ferreira FO, Ferrigno R, David Filho WJ, Nishimoto IN, Vieira RAC, Lopes A: **Chemoradiation instead of surgery to treat mid and low rectal tumors: Is it safe?** *Annals of Surgical Oncology* 2002, **9**:568-573.
47. Hyams DM, Mamounas EP, Petrelli N: **A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R0-3.** *Dis Colon Rectum* 1997, **40**:131-139.
48. Mohiuddin M, Regine WF, Marks GJ, Marks JW: **High-dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal 2 cm of the rectum.** *Int J Radiat Oncol Biol Phys* 1998, **40**:569-574.
49. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH, Janjan NA: **Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma.** *Cancer* 2003, **97**:517-524.
50. Osti MF, Valeriani M, Masoni L, Tombolini V, Enrici RM: **Neoadjuvant chemoradiation for locally advanced carcinoma of the rectum.** *Tumori* 2004, **90**:302-309.
51. Crane CH, Skibber J: **Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.** *Semin Surg Oncol* 2003, **21**:265-270.
52. Crane CH, Skibber JM, Birnbaum EH, Feig BW, Singh AK, Delclos ME, Lin EH, Fleshman JW, Thames HD, Kodner IJ, Lockett MA, Picus J, Phan T, Chandra A, Janjan NA, Read TE, Myerson RJ: **The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.** *Int J Radiat Oncol Biol Phys* 2003, **57**:84-89.
53. Francois Y, Memoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP: **Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial.** *J Clin Oncol* 1999, **17**:2396-2402.
54. Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Morganti AG, Barbaro B, Rotman M: **Preoperative chemoradiation for extra-peritoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation.** *Int J Radiat Oncol Biol Phys* 1998, **40**:1067-1075.
55. Mohiuddin M, Marks J, Marks G: **The adequacy of distal surgical margin following high dose preoperative radiation and sphincter preservation surgery for rectal cancer.** *Int J Radiat Oncol Biol Phys* 2004, **57(2S)**:S383.
56. Kuvshinov B, Maghfoor I, Miedema B, Bryer M, Westgate S, Wilkes J, Ota D: **Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient?** *Ann Surg Oncol* 2001, **8**:163-169.
57. Luana-Perez P, Segura J, Alvarado I: **Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy.** *Ann Surg Oncol* 2000, **7**:727-731.
58. Villafranca E, Okruzhnov Y, Domiguez MA: **Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.** *J Clin Oncol* 2001, **19**:1779-1786.
59. Esposito G, Pucciarelli S, Alaggio R: **P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer.** *Ann Surg Oncol* 2001, **8**:311-318.
60. Saw RPM, Morgan M, Koorey D: **p53, deleted in colorectal cancer gene, and thymidylase synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.** *Dis Colon Rectum* 2003, **46**:192-202.
61. Rodel C, Grabenbauer GG, Papadopoulos T: **Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer.** *Int J Radiat Oncol Biol Phys* 2002, **52**:294-303.
62. Giralt J, Eraso A, Armengol M: **Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.** *Int J Radiat Oncol Biol Phys* 2002, **54**:1460-1465.
63. Kandioler D, Zwrtek R, Ludwig C: **TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer.** *Ann Surg* 2002, **235**:493-498.
64. Adell G, Zhang H, Jansson A: **Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer.** *Int J Radiat Oncol Biol Phys* 2001, **50**:659-663.
65. Hiots SP, Weber SM, Cohen AM, Minsky BD, Paaty PB, Guillem JG, Wagman R, Saltz LB, Wong MD: **Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients.** *Int J Radiat Oncol Biol Phys* 2002, **194**:131-136.
66. Allal AS, Gervaz P, Gertsch P, Bernier J, Roth AD, Morel P, Bieri S: **Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study.** *Int J Radiat Oncol Biol Phys* 2005, **61**:1129-1135.
67. Marijnen CA, van de Velde CJ, Putter H, van denBrink M, Maas CP, Martijn H, Rutten HJ, Wiggers T, Kranenbarg EK, Leer JW, Stiggelbout AM: **Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.** *J Clin Oncol* 2005, **23**:1847-1858.
68. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, Minsky BD, Wong MD: **Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.** *Ann Surg* 2005, **241**:829-836.
69. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M: **Complete pathologic response following**

- preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.** *Dis Colon Rectum* 2004, **47**:1798-1807.
70. Onaitis MW, Noone RB, Fields R: **Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.** *Ann Surg Oncol* 2001, **8**:801-806.
 71. Stein DE, Mahmoud NN, Anne PR: **Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.** *Dis Colon Rectum* 2003, **46**:448-453.
 72. Brown CL, Ternent CA, Thorson AG, Christensen MA, Blatchford GJ, Shashidharan M, Haynatzki GR: **Response to preoperative chemoradiation in stage II and III rectal cancer.** *Dis Colon Rectum* 2003, **46**:1189-1193.
 73. Janjan NA, Crane C, Feig BW: **Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer.** *Am J Clin Oncol* 2001, **24**:107-112.
 74. Mohiuddin M, Hayne M, Regine WF: **Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers.** *Int J Radiat Oncol Biol Phys* 2000, **48**:1075-1080.
 75. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P: **A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision.** *Dis Colon Rectum* 2003, **46**:298-304.
 76. Ruo L, Tickoo S, Klimstra DS: **Long-term prognostic significance of extend of rectal cancer response to preoperative radiation and chemotherapy.** *Ann Surg* 2002, **236**:75-81.
 77. Valentine V, Coco C, Picciocchi A, Cellini N, Fares MC, Tedesco M, Cosimelli M, Rotman M: **Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long term analysis of 165 patients.** *Int J Radiat Oncol Biol Phys* 2002, **53**:664-674.
 78. Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L, Maingon P, Bardet E, Peirart M, Briffaux A: **Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group.** *Eur J Cancer* 2004, **40**:219-224.
 79. Ciernik IF, Huser M, Burger C, Davis JB, Szekely G: **Automated functional image-guided radiation treatment planning for rectal cancer.** *Int J Radiat Oncol Biol Phys* 2005, **62**:893-900.
 80. Nuyttens JJ, Robertson JM, Yan D, Martinez A: **The influence of small bowel motion on both a conventional three-fields and intensity modulated radiation therapy (IMRT) for rectal cancer.** *Cancer Radiother* 2004, **8**:297-304.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

